Ally Bridge Group

Kandu Health is a technology-driven healthcare company focused on enhancing the quality of life for stroke survivors and their families. The company specializes in stroke recovery training, stroke detection research, and educational services. Kandu Health provides remote clinical support through its application, which delivers personalized information, resources, and guidance tailored to each participant. This approach empowers stroke survivors to take charge of their recovery and assists them in adapting to life after a stroke.

The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent, which means that a single GEMS design can address the majority or all genetic subtypes of a disease.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly for patients with mTOR pathway driver alterations, such as those involving the TSC1 or TSC2 genes. Aadi's primary aim is to create transformational therapies for patients with specific cancer types, including the ultra-rare perivascular epithelioid cell tumor (PEComa). The company addresses challenges faced by existing mTOR inhibitors, including issues related to pharmacology, drug delivery, safety, and targeting. Founded in 2011, Aadi Bioscience has positioned itself to innovate in the treatment of oncology and cardiovascular diseases.

VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs that target G protein-coupled receptors (GPCRs). With a focus on therapeutic proteins and antibodies, Tectonic aims to address the complexities of GPCR-targeted drug discovery through its proprietary technology platform, GEODe. The company is committed to unlocking the therapeutic potential of challenging receptors, striving to create biologic medicines that can effectively modify disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic combines a strong scientific foundation with a history of entrepreneurial success to advance its mission in the biopharmaceutical landscape.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Founded in 2011, the company develops therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, addressing underlying causes of conditions like nasal obstruction and chronic rhinitis. Its flagship products include the VivAer procedure and device for nasal airway obstruction, as well as the RhinAer procedure and device for chronic rhinitis. These innovative offerings enable ENT physicians to provide effective treatments in an office setting, often with local anesthesia and little to no downtime for patients, making them appealing alternatives to traditional invasive surgeries.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly for patients with mTOR pathway driver alterations, such as those involving the TSC1 or TSC2 genes. Aadi's primary aim is to create transformational therapies for patients with specific cancer types, including the ultra-rare perivascular epithelioid cell tumor (PEComa). The company addresses challenges faced by existing mTOR inhibitors, including issues related to pharmacology, drug delivery, safety, and targeting. Founded in 2011, Aadi Bioscience has positioned itself to innovate in the treatment of oncology and cardiovascular diseases.

ProMIS Neurosciences, Inc. is a development-stage biotechnology company based in Toronto, Canada, focused on developing precision therapeutic solutions for neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Established in 2004, the company employs a proprietary target discovery engine that integrates thermodynamic and computational techniques to identify disease-specific epitopes on misfolded proteins. Its lead product candidates include PMN310, PMN350, and PMN330, which are monoclonal antibodies targeting toxic forms of amyloid beta oligomers and prion-like proteins associated with AD. Additionally, ProMIS is developing treatments targeting the neurotoxic tau protein in AD and proteins linked to ALS and PD. The company collaborates with BC Neuroimmunology to advance proprietary diagnostic assays and blood-based tests for Alzheimer’s disease, enhancing early detection and treatment efficacy. Formerly known as Amorfix Life Sciences Ltd., ProMIS Neurosciences has rebranded itself to reflect its focus on neurological therapeutics.

Kestra Medical Technologies, Inc. is a company that specializes in developing and manufacturing wearable medical devices aimed at monitoring and managing acute medical conditions. Founded in 2014 and headquartered in Kirkland, Washington, the company offers solutions that enable the collection, communication, and storage of patient performance data, facilitating both real-time and retrospective analysis. Among its key products are wearable cardioverter defibrillators designed to prevent sudden cardiac death and aid in the recovery of at-risk cardiac patients. By focusing on intuitive and mobile diagnostic and therapeutic technologies, Kestra Medical Technologies strives to enhance patient care and support healthcare teams in effectively managing patient health.

InSightec Ltd. is a pioneering company based in Tirat Carmel, Israel, specializing in non-invasive medical treatments through its Exablate platform, which employs MR guided focused ultrasound technology. Founded in 1999, InSightec develops and distributes systems that address various oncology and gynecology conditions, including the Exablate Neuro for personalized thalamotomy in movement disorders and pain management. The Exablate system has received multiple regulatory approvals, including CE marks and FDA approval, for treatments of symptomatic uterine fibroids, pain from bone metastases, and adenomyosis. The company provides comprehensive support services, including onsite clinical training and maintenance, to medical professionals using its technology in facilities across Israel and internationally. InSightec maintains a strategic partnership with Lantheus Holdings and has expanded its presence in Europe, Asia, and the Americas, earning recognition for its innovative contributions to the field of acoustic surgery.

Context Therapeutics LLC is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative therapies for hormone-responsive cancers. Founded in 2015, the company is dedicated to creating new medicines primarily for female cancers, including breast, ovarian, and endometrial cancer. Its lead program, Apristor (Onapristone XR), is an investigational Phase 2 drug targeting progesterone receptor positive metastatic breast and ovarian cancers. In addition to Apristor, Context is advancing CTX-030916, a potential oral antiprogestin for treating uterine fibroids and endometriosis. The company is also developing a preclinical program, CTIM-76, which is a bispecific antibody designed to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. Through its innovative pipeline, Context Therapeutics aims to address unmet medical needs in the treatment of solid tumors.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with additional operations in the United States and Australia. The company specializes in developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant underserved population. Mainstay Medical has created an FDA-approved restorative treatment designed to enhance muscle control and improve functionality in the lumbar spine. This therapy aims to help patients regain mobility and enhance their overall quality of life. By collaborating with scientists and clinical experts, Mainstay Medical is committed to advancing solutions for those affected by debilitating back pain.

Skye Bioscience is a San Diego-based pharmaceutical company focused on developing innovative therapeutic solutions for prevalent diseases that lack effective treatments. The company specializes in creating proprietary molecules aimed at addressing inflammatory, fibrotic, and metabolic disorders. It is particularly engaged in the modulation of cannabinoid receptor 1 (CB1) to provide novel treatment options for conditions such as obesity and glaucoma. Among its clinical candidates, Skye Bioscience is advancing nimacimab, an antibody designed to inhibit peripheral CB1 receptors for obesity treatment, and SBI-100 Ophthalmic Emulsion, a CB1 agonist intended for glaucoma management. The company's commitment to research and development positions it to contribute significantly to the biopharmaceutical landscape, particularly in the realm of cannabinoid-based therapeutics.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Vida Health, Inc. is a virtual care company based in San Francisco, California, focused on addressing chronic physical and behavioral health conditions. The company provides a comprehensive platform that integrates mental and physical health treatment, utilizing a clinically validated approach that combines artificial intelligence with personalized support from human coaches and licensed therapists. Through its application, users have access to video sessions, messaging, and tailored digital content designed to help them prevent, manage, and reverse chronic conditions such as diabetes and hypertension, alongside related mental health issues like stress and anxiety. Founded in 2012 and originally known as Via Health, Inc., Vida Health aims to treat the whole health of individuals by tackling the root causes of their conditions.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

ProMIS Neurosciences, Inc. is a development-stage biotechnology company based in Toronto, Canada, focused on developing precision therapeutic solutions for neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Established in 2004, the company employs a proprietary target discovery engine that integrates thermodynamic and computational techniques to identify disease-specific epitopes on misfolded proteins. Its lead product candidates include PMN310, PMN350, and PMN330, which are monoclonal antibodies targeting toxic forms of amyloid beta oligomers and prion-like proteins associated with AD. Additionally, ProMIS is developing treatments targeting the neurotoxic tau protein in AD and proteins linked to ALS and PD. The company collaborates with BC Neuroimmunology to advance proprietary diagnostic assays and blood-based tests for Alzheimer’s disease, enhancing early detection and treatment efficacy. Formerly known as Amorfix Life Sciences Ltd., ProMIS Neurosciences has rebranded itself to reflect its focus on neurological therapeutics.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

LightForce Orthodontics, Inc., established in 2015 and headquartered in Cambridge, Massachusetts, specializes in manufacturing customized 3D-printed orthodontic braces and accessories. The company's flagship product, Cloud Brackets, are precision-manufactured in white ceramic polycrystalline alumina, offering precise slot dimensions and contoured edges. LightForce also produces LightTray, a 3D-printed indirect bonding tray optimized for accuracy, and TurboTrays, aiding in bite correction. Their digital platform facilitates collaboration between orthodontists and LightForce technicians, enabling patient-specific treatment plans. The company aims to enhance the orthodontic experience for both patients and practitioners by applying modern technology and mass customization.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

Ceribell, Inc. is a medical technology company based in Mountain View, California, that specializes in the design and manufacture of devices for acquiring and interpreting electroencephalography (EEG) data. Founded in 2014, Ceribell focuses on making EEG technology more accessible, efficient, and cost-effective, particularly in acute care settings. The company's flagship product, the Ceribell EEG System, includes a portable EEG headband and a compact recorder that provide clinical-quality EEG results without the need for a trained EEG technologist. This system can be set up by healthcare providers in just six minutes, facilitating quicker clinical decision-making. An innovative feature of the Ceribell System is its Brain Stethoscope function, which translates brainwave patterns into sound to aid in the detection of seizures, including non-convulsive seizures. This capability enables earlier diagnosis and targeted treatment, potentially reducing mortality, length of hospital stays, and the risk of complications for patients with serious neurological conditions.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Founded in 2011, the company develops therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, addressing underlying causes of conditions like nasal obstruction and chronic rhinitis. Its flagship products include the VivAer procedure and device for nasal airway obstruction, as well as the RhinAer procedure and device for chronic rhinitis. These innovative offerings enable ENT physicians to provide effective treatments in an office setting, often with local anesthesia and little to no downtime for patients, making them appealing alternatives to traditional invasive surgeries.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Quantum Surgical is a company focused on advancing minimally invasive treatments for liver cancer through the development of surgical robotics. Its mission is to democratize access to effective treatment options for this condition. By providing intelligent tools designed for advanced percutaneous ablation therapy, Quantum Surgical aims to enhance the capabilities of healthcare providers, allowing them to improve patient outcomes and deliver safer interventional oncology procedures. The company is dedicated to transforming the surgical landscape for liver cancer, ensuring that more patients can benefit from innovative and less invasive treatment options.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Imperative Care, Inc. is a medical technology company based in Campbell, California, established in 2015. The company specializes in developing innovative solutions aimed at enhancing the diagnosis, treatment, and rehabilitation of stroke patients. Its primary offerings include the Large Distal Platform, a catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic stroke procedures, and the ZOOM Aspiration System, which works in conjunction with the Large Distal Platform to provide a comprehensive solution for clot removal across various occlusion sizes. By focusing on improving the speed and effectiveness of acute stroke treatment, Imperative Care aims to address significant unmet needs in stroke care, ultimately providing patients with better prospects for recovery.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development and manufacturing of reagents for marker multiplexing detection and analysis. Founded in 2015, the company focuses on tissue imaging, diagnostics, and multiplexing to enhance research in the life sciences and biomedical fields. Ultivue's innovative technologies, including DNA-PAINT and DNA-Exchange, facilitate the collection of high-resolution microscopic images that contribute to a deeper understanding of biological processes and diseases. The company’s multiplex biomarker assays are designed for tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine. Ultivue's products are intended for fluorescent microscopy-based research and hold potential for clinical diagnostic applications.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with additional operations in the United States and Australia. The company specializes in developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant underserved population. Mainstay Medical has created an FDA-approved restorative treatment designed to enhance muscle control and improve functionality in the lumbar spine. This therapy aims to help patients regain mobility and enhance their overall quality of life. By collaborating with scientists and clinical experts, Mainstay Medical is committed to advancing solutions for those affected by debilitating back pain.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

MedAvail Holdings, Inc. is a technology-enabled pharmacy company based in Mississauga, Canada, specializing in the integration of automated pharmacy services within clinics and other healthcare settings. The company operates primarily through two segments: Retail Pharmacy Services and Pharmacy Technology. Its Retail Pharmacy Services segment generates most of its revenue by operating SpotRx, a full-service retail pharmacy that utilizes MedAvail's automated technology, primarily serving Medicare patients in the United States. The Pharmacy Technology segment focuses on the development and commercialization of the MedAvail MedCenter, an advanced robotic dispensing platform that can be sold or leased to third-party clients. Additionally, MedAvail offers telehealth solutions, enabling remote consultations with pharmacists via on-site kiosks and home delivery services.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Vida Health, Inc. is a virtual care company based in San Francisco, California, focused on addressing chronic physical and behavioral health conditions. The company provides a comprehensive platform that integrates mental and physical health treatment, utilizing a clinically validated approach that combines artificial intelligence with personalized support from human coaches and licensed therapists. Through its application, users have access to video sessions, messaging, and tailored digital content designed to help them prevent, manage, and reverse chronic conditions such as diabetes and hypertension, alongside related mental health issues like stress and anxiety. Founded in 2012 and originally known as Via Health, Inc., Vida Health aims to treat the whole health of individuals by tackling the root causes of their conditions.

Mavrik Dental Systems Ltd. is a company dedicated to developing and commercializing innovative biocompatible products for the professional dental market. Founded in 2012 and headquartered in Costa Mesa, California, with an additional office in Raanana, Israel, Mavrik has created a fully automated treatment delivery platform that aims to enhance in-office dental therapies. This platform allows dentists to perform effective teeth whitening procedures with reduced discomfort, addressing the lack of innovation in dental practices. The company's product offerings include thera smile for teeth whitening, thera natural E for gum disease treatment, and denti sense for sensitivity management. Mavrik’s technology not only improves treatment efficacy and patient satisfaction but also enables dental hygienists to perform tasks more efficiently, ultimately increasing practice revenue. By integrating cutting-edge technology and industry expertise, Mavrik Dental Systems is poised to transform the dental industry and enhance patient care.

Imperative Care, Inc. is a medical technology company based in Campbell, California, established in 2015. The company specializes in developing innovative solutions aimed at enhancing the diagnosis, treatment, and rehabilitation of stroke patients. Its primary offerings include the Large Distal Platform, a catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic stroke procedures, and the ZOOM Aspiration System, which works in conjunction with the Large Distal Platform to provide a comprehensive solution for clot removal across various occlusion sizes. By focusing on improving the speed and effectiveness of acute stroke treatment, Imperative Care aims to address significant unmet needs in stroke care, ultimately providing patients with better prospects for recovery.

Venclose, Inc. is a medical technology company based in San Jose, California, founded in 2014. The company specializes in developing endovenous radiofrequency ablation therapy systems aimed at treating chronic venous insufficiency. Venclose's technology focuses on improving both the physician and patient experience during the treatment of damaged veins. The company's solutions facilitate ease of navigation and positioning during procedures, minimize invasiveness, and provide real-time data to inform treatment decisions. By enabling a straightforward catheter plug-in, Venclose empowers medical professionals to effectively address venous reflux, ultimately restoring healthy blood flow in patients.

Jinxin Fertility Group Limited is a prominent provider of assisted reproductive services (ARS) with operations in China and the United States. Established in 2003 and headquartered in Chengdu, China, the company offers various treatment options, including artificial insemination with either the patient's or donor's sperm and in vitro fertilization (IVF) techniques, such as conventional IVF and intracytoplasmic sperm injection (ICSI). In addition to reproductive services, Jinxin Fertility provides complementary offerings like nutrition guidance, Chinese medicine treatment, and psychological counseling to enhance patient support. The company operates several subsidiaries, including Chengdu Xinan and Shenzhen Zhongshan, as well as HRC in the United States, thereby expanding its network and service capabilities. Jinxin Fertility's commitment to high-quality care and innovative reproductive solutions has positioned it as a leader in the field.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Shanghai Duoning Biotechnology Co., Ltd. specializes in the development of serum-free, personalized, and chemically defined cell culture media for the biopharmaceutical industry. Founded in 2005 and based in Shanghai, the company offers a range of products, including basic media, feed media, and cell therapy media. Duoning Biotech is dedicated to providing tailored media development, cell culture process optimization, and commissioned formula production services, utilizing its expertise in animal cell culture concepts. The company supports the research, development, and commercialization of biologics products by delivering comprehensive solutions that encompass technical support and customized services tailored to the needs of pharmaceutical and scientific research institutions.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Akeso Biopharma, Inc. is a contract research organization based in Zhongshan, China, specializing in the discovery and development of antibody and protein drugs. Established in 2012, the company offers a range of integrated services to both domestic and international pharmaceutical firms, including protein expression and purification, antibody generation, assay development, humanization, and affinity maturation. Akeso has developed a comprehensive biopharmaceutical research and development platform, focusing on therapeutic areas such as cancer, autoimmune diseases, inflammation, and cardiovascular diseases. With a robust pipeline of over 30 drug candidates, 17 of which are in clinical stages, Akeso is recognized for its innovative approaches, including the development of first-in-class bi-specific antibody drugs. The company collaborates with various pharmaceutical enterprises to advance the joint development of new drugs, positioning itself as a leader in the biopharmaceutical industry.

I-Mab Biopharma (Shanghai) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, with additional offices in Beijing and Rockville, Maryland. Founded in 2016, the company focuses on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and immuno-inflammation. I-Mab's diverse drug pipeline targets various therapeutic areas, including multiple myeloma, autoimmune diseases, pediatric growth hormone deficiency, and several cancer indications such as head and neck cancer. Key candidates in its portfolio include Uliledlimab, an antibody for solid tumors, along with Ragistomig and Givastomig, highlighting the company's commitment to developing transformative therapies for patients.

Quantum Surgical is a company focused on advancing minimally invasive treatments for liver cancer through the development of surgical robotics. Its mission is to democratize access to effective treatment options for this condition. By providing intelligent tools designed for advanced percutaneous ablation therapy, Quantum Surgical aims to enhance the capabilities of healthcare providers, allowing them to improve patient outcomes and deliver safer interventional oncology procedures. The company is dedicated to transforming the surgical landscape for liver cancer, ensuring that more patients can benefit from innovative and less invasive treatment options.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Alzheon, Inc. is a clinical-stage biopharmaceutical company based in Framingham, Massachusetts, focused on developing innovative treatments for Alzheimer’s disease and other neurodegenerative disorders. Founded in 2013, the company’s lead product, ALZ-801, is an orally administered inhibitor designed to prevent beta amyloid misfolding and is currently in Phase III clinical trials. Alzheon is also advancing its preclinical candidate, ALZ-1903, which is a potent inhibitor of beta amyloid misfolding. The company aims to improve the cognitive and functional health of patients by building a pipeline of transformative drugs that address the complexities of neurodegeneration, leveraging a small molecule-based drug discovery platform to develop oral therapies that target amyloid neurotoxicity.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Wacai is a Chinese mobile app developer specializing in personal finance management through its widely-used mobile application. Since its launch in 2009, the app has provided users with bookkeeping services and expanded its functionality to include mutual fund trading in 2013. In 2014, Wacai introduced a credit card manager feature, which has become increasingly popular among users in China. The app aims to help individuals manage their finances effectively by offering tools for personal bookkeeping, credit management, and an online community for financial assistance. With a user base exceeding 40 million, Wacai continues to enhance its platform to meet the evolving needs of its clientele.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer, autoimmune diseases, inflammatory conditions, and neurodegenerative disorders. The company leverages its proprietary G-MAB antibody library to create a diverse range of treatments, including chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates. Key products in development include anti-CD38 CAR-T therapy for multiple myeloma and a non-opioid neurotoxin, resiniferatoxin, aimed at treating severe pain in late-stage cancer and osteoarthritis. Sorrento also explores drug delivery technologies such as Sofusa, which targets the lymphatic system, and ZTlido, a lidocaine delivery system for postherpetic neuralgia. Additionally, the company is involved in various collaborations to enhance its research and development efforts, including projects focused on COVID-19 therapeutics. With a commitment to addressing significant unmet medical needs, Sorrento Therapeutics aims to advance its diverse pipeline through both innovative drug development and strategic partnerships.

LinkDoc Technology Limited, founded in 2014 and headquartered in Beijing, China, specializes in developing medical data solutions and big data platforms focused on oncology. The company provides clinical structured data services to oncology hospitals, enabling them to address scientific and clinical challenges effectively. LinkDoc is dedicated to offering continuous care for patients with critical diseases and delivers data-driven precision life sciences solutions that facilitate clinical research and enhance real-world adoption for life sciences companies and healthcare providers. Additionally, LinkDoc ensures that its private hospital deployments comply with US HIPAA Act standards, implementing robust security measures to protect patient privacy and data integrity.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Tunitas Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, focused on developing innovative protein therapeutics for allergy sufferers. Founded in 2007, the company specializes in creating genetically engineered fusion proteins, including its lead product, Epsi-gam, which combines human IgE and IgG1 components. These therapeutics aim to target and inhibit key pathways involved in allergic reactions, thereby disrupting the production of IgE, the antibody responsible for triggering allergic responses. Tunitas Therapeutics seeks to provide patients with effective treatment options for various IgE-mediated diseases, such as asthma and severe food allergies, through a regimen administered in their allergists’ offices. The company's mission is to significantly improve the quality of life for individuals suffering from serious allergic conditions.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Alzheon, Inc. is a clinical-stage biopharmaceutical company based in Framingham, Massachusetts, focused on developing innovative treatments for Alzheimer’s disease and other neurodegenerative disorders. Founded in 2013, the company’s lead product, ALZ-801, is an orally administered inhibitor designed to prevent beta amyloid misfolding and is currently in Phase III clinical trials. Alzheon is also advancing its preclinical candidate, ALZ-1903, which is a potent inhibitor of beta amyloid misfolding. The company aims to improve the cognitive and functional health of patients by building a pipeline of transformative drugs that address the complexities of neurodegeneration, leveraging a small molecule-based drug discovery platform to develop oral therapies that target amyloid neurotoxicity.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing innovative therapeutics for oncology and infectious diseases, with a particular emphasis on targeting dysfunctional lipid metabolism pathways. The company has a strong focus on fatty acid synthase (FASN) biology and has developed a pipeline of proprietary FASN inhibitors. Its lead product candidate, denifanstat, is an oral selective FASN inhibitor being investigated for the treatment of nonalcoholic steatohepatitis (NASH). Additionally, Sagimet is exploring antiviral therapeutic candidates aimed at treating respiratory syncytial virus, cytomegalovirus, and other human pathogens. Founded in 2006, Sagimet Biosciences was previously known as 3-V Biosciences, Inc. before rebranding in August 2019.

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the development of anticalin-based therapeutics for treating various medical conditions, including cancer and severe asthma. Anticalins are engineered proteins derived from lipocalins, naturally occurring human proteins that can bind and transport a variety of molecules. The company's lead programs include PRS-060, a drug candidate in Phase I clinical trials targeting IL-4Ra for asthma and inflammatory diseases, and PRS-343, a bispecific protein in Phase I trials for oncology. Pieris is also advancing PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development, and PRS-080, currently in Phase IIa trials for targeting hepcidin in patients with functional iron deficiency. Pieris collaborates with strategic partners and research institutions to enhance its development efforts, showcasing a robust pipeline aimed at addressing significant unmet medical needs. The company was founded in 2000 and is recognized for its innovative approach in biotherapeutics.

Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

ImmunGene Inc. is a biotechnology company based in Thousand Oaks, California, specializing in the discovery and development of monoclonal antibody-based therapeutics for cancer, autoimmune disorders, and other diseases. Founded in 2007, the company has developed a diverse pipeline of products, including IGN002 for non-Hodgkin lymphoma, IGN001 for breast cancer, IGN003 for multiple myeloma, IGN004 for solid tumors and melanomas, IGN005 for acute myeloid leukemia, and IGN006 for various solid tumors. Additionally, ImmunGene has established a joint venture, Valor Biotherapeutics, LLC, with Caliber Biotherapeutics, LLC, aimed at advancing monoclonal antibody-interferon fusion proteins for cancer treatment. The company's focus on proprietary antibody-cytokine fusion technology positions it to offer innovative therapeutic solutions in the healthcare sector.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.